On October 22–23, 2026, the Hotel Parque Central will host the “Workshop on Biosimilars: Innovation and Access in Healthcare,” organized by the import-export company FARMACUBA, the entity announced.
RELATED:
Cuban Sciences Academy Awards Prize for Regenerative Medicine Research
Over the course of two days, specialists and institutions from the biotechnology, pharmaceutical, and healthcare sectors will share experiences regarding the introduction, regulation, clinical evaluation, commercialization, and medical applications of biosimilars in Cuba.
The program includes panels on the policy, introduction, and final processing of biosimilars in Cuba; commercialization and promotion strategies; as well as regulatory aspects, clinical evaluation, and the medical applications of these products.
FARMACUBA will present information on the biosimilars for which it holds the rights, and will discuss market opportunities and economic benefits linked to their development and commercialization. The event will also provide an opportunity to establish connections with Cuban representative offices abroad, embassies, and potential international clients.
Presentation of Rituximab
A key highlight will be the official presentation of Rituximab, identified as the first biosimilar to undergo final processing in Cuban biopharmaceutical facilities. During the workshop, its regulatory and clinical outcomes, medical applications, and aspects related to its introduction and commercialization within the National Health System will be presented.
The second day will feature interactive virtual meetings with Cuban representatives abroad, embassies, and prospective foreign buyers. This initiative aims to promote the international reach of biosimilars developed under the auspices of FARMACUBA.
Additionally, a catalog of biosimilars will be presented, and the role of Rituximab in the treatment of B-cell lymphomas will be examined.
The workshop will serve as a forum for exchange among national and international specialists, intended to expand knowledge, explore avenues for collaboration, and examine new alternatives for the development and commercialization of biosimilars in Cuba.
FARMACUBA
Facilitator in the introduction and commercialization of biosimilars, strengthening the link between pharmaceutical innovation and national healthcare.
As an importer, exporter, distributor, and marketer of pharmaceutical products, the company is part of the BioCubaFarma business group, which operates under the Council of Ministers of the Republic of Cuba.
It ensures the provision of necessary resources to the Cuban pharmaceutical industry, while also managing the export of medicines and technical services to international clients.
In line with the country’s new economic and commercial strategy—designed to boost the development of the business sector—FARMACUBA aims to set a benchmark both domestically and internationally within the pharmaceutical industry. This presents a unique opportunity to expand knowledge, forge strategic alliances, and explore new avenues for collaboration.
We went aboard a cruise ship navigating some of the world's most dangerous waters. In the Arctic, drifting icebergs, sea ice, sudden storms and fierce winds make sailing unpredictable. Yet every year, around 100,000 cruise passengers travel to Greenland to explore its remote coastline and experience one of the world's last great wildernesses.
Pope Leo XIV called Russian President Vladimir Putin while recovering from surgery in the hospital to urge him to call a ceasefire in the city of Oleshky in Ukraine.
"During the conversation, the Holy Father expressed his deep concern about the grave humanitarian situation in the city of Oleshky, in the Kherson region, and called for a ceasefire to allow the delivery of food and medical assistance and the voluntary and safe evacuation of the civilian population," the Vatican said in a statement.
"Finally, the Holy Father reaffirmed the Holy See’s commitment to promoting dialogue and peace."
TRUMP ANNOUNCES IMMEDIATE ENERGY CEASEFIRE BETWEEN RUSSIA AND UKRAINE
The situation in Oleshky is dire with no humanitarian food deliveries allowed in the Russian-controlled city since May. It also has no electricity, gas or running water, and the hospital is barely functional.
The pope was diagnosed with lung cancer Tuesday and underwent a procedure to remove the lower lobe of his right lung.
The 71-year-old remained in the hospital recovering on Friday but seemed to be doing well.
Along with the call, he held Mass in a makeshift hospital chapel, and the Vatican released the first images of him since his surgery, which showed him standing at an altar.
POPE LEO XIV SEEN FOR FIRST TIME SINCE LUNG CANCER SURGERY AMID MAJOR RECOVERY MILESTONE
His doctors said he showed "continued improvement."
"His post-operative recovery allows him to carry out his normal daily activities completely on his own," a medical update signed by his personal physician, Luigi Carbone, and the head of thoracic surgery at Gemelli, Dr. Stefano Margaritora, said.
The pope is expected to deliver his traditional Angelus prayer service on Sunday either from the hospital or the Vatican.
He is also still expected to travel to Uruguay, Argentina and Peru starting Nov. 6 as planned.
The Kremlin blames Ukraine for the situation in Oleshky with Putin giving the pope a "detailed explanation regarding the Kyiv regime’s responsibility for the difficult humanitarian situation there," the Kremlin said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Putin also supports "the Vatican’s intention to help create conditions for ensuring the safety of the local population and facilitating the delivery of essential supplies," the Kremin added.
South Korean memory chipmakers must secure new United States licenses by year-end to keep shipping top-end American tools to their Chinese factories, after the Trump administration scrapped blanket permits last year. To win the permits, SK Hynix and Samsung must promise to build or expand factories in the US. SK Hynix’s one-year license to ship […]
The post SK Hynix needs a Trump 2027 deal to expand its Dalian NAND fab appeared first on Asia Times.
Login